Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchSpecialized Academic Departments and Institutes
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges without Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

University of Alabama at Birmingham

United States
6 Trials1 Paper

Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.

Academic Research

1 papers

Published Papers

1

Trial Involvement

6

Distinct Focus Topics

0

Latest Publication

Mar 10, 2026

Quick Facts

Type
Other
HQ
United States
Website
Visit

Sponsored Trials

5
RecruitingI

Exploratory Study of Low Dose Psilocybin

Start Date
Compounds
Placebo, Psilocybin
RecruitingI

Psilocybin-facilitated Treatment for Chronic Pain

Start Date
Compounds
Psilocybin, Placebo
CompletedII

Psilocybin-facilitated Treatment for Cocaine Use

Start Date
Compounds
Psilocybin, Placebo
CompletedII

miRNAs, Suicide, and Ketamine – Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

Start Date
Compounds
Ketamine
CompletedNA

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

Start Date
Compounds
Ketamine, Placebo

Collaborated Trials

1
RecruitingII

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Start Date
Compounds
Psilocybin, Placebo

Research Papers

1
Open AccessindividualPrimary

Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial

This pilot randomised clinical trial (n=82) found that a single dose of psilocybin (30mg/70kg) combined with cognitive behavioural therapy produced significantly higher long-term smoking abstinence rates at 6 months compared to nicotine patches plus CBT (41% vs 10%), with no serious adverse events attributed to either treatment.

Published
Journal
JAMA Network Open
Authors
Johnson, M. W., Naudé, G. P., Hendricks, P. S., Garcia-Romeu, A.